MADYOASIS DIAGNOSTICS

Patient Name : **MRS. POONAM TEKWANI**
Age/Gender : 34 years (Female)
Mobile No. : -

Referral : SELF
Source : **MEDIHOME**
Sample Collected : Nov 30, 2022, 01:02 p.m.
Sample Received : Nov 30, 2022, 01:02 p.m.
Approved Date : Nov 30, 2022, 04:54 p.m.
Sample ID : 002233422

Test Description	Value(s)	Reference Range	
Cbc With Esr			
Hemoglobin (Hb)	**11.1**	12.0 - 15.0	gm/dL
Erythrocyte (RBC) Count	**3.56**	3.8 - 4.8	mil/cu.mm
Packed Cell Volume (PCV)	36.9	36 - 46	%
Mean Cell Volume (MCV)	**103.65**	83 - 101	fL
Mean Cell Haemoglobin (MCH)	31.18	27 - 32	pg
Mean Corpuscular Hb Concn. (MCHC)	**30.08**	31.5 - 34.5	g/dL
Red Cell Distribution Width (RDW)	12.5	11.6 - 14.0	%
Total Leucocytes (WBC) Count	6500	4000-10000	cell/cu.mm
Neutrophils	65	40 - 80	%
Lymphocytes	27	20 - 40	%
Monocytes	05	2 - 10	%
Eosinophils	02	1 - 6	%
Basophils	1	1-2	%
Absolute Neutrophil Count	4225	2000 - 7000	/c.mm
Absolute Lymphocyte Count	1755	1000 - 3000	/c.mm
Absolute Monocyte Count	325	200 - 1000	/c.mm
Absolute Eosinophil Count	130	20 - 500	/c.mm
Absolute Basophils Count	65	20 - 100	/c.mm
Platelet Count	356	150 - 410	10^3/ul
WBC Morphology	Within normal limits		
Platelet Morphology	Adequate on smear		
RBC Morphology	Normocytic normochromic		
ESR - Erythrocyte Sedimentation Rate	11	0 - 29	mm/hr
Method : EDTA Whole Blood, Manual Westergren			

END OF REPORT

Dr. Mohole Bhupendra D.
MBBS, DCP
Reg. No. 87139

MADYOASIS DIAGNOSTICS

Patient Name : **MRS. POONAM TEKWANI**
Age/Gender : 34 years (Female)
Mobile No. : -

Referral : SELF
Source : **MEDIHOME**
Sample Collected : Nov 30, 2022, 01:02 p.m.
Sample Received : Nov 30, 2022, 01:02 p.m.
Approved Date : Nov 30, 2022, 04:54 p.m.
Sample ID : 002233422

Test Description	Value(s)	Reference Range
Blood Group Abo & Rh Typing, Blood		
Blood Group (ABO typing) Method : Manual-Hemagglutination	"O"	
RhD Factor (Rh Typing) Method : Manual hemagglutination	Positive	

END OF REPORT

Dr. Mohole Bhupendra D.
MBBS, DCP
Reg. No. 87319

MADYOASIS DIAGNOSTICS

Patient Name : **MRS. POONAM TEKWANI**
Age/Gender : 34 years (Female)
Mobile No. : -

Referral : SELF
Source : **MEDIHOME**
Sample Collected : Nov 30, 2022, 01:02 p.m.
Sample Received : Nov 30, 2022, 01:02 p.m.
Approved Date : Nov 30, 2022, 04:54 p.m.
Sample ID : 002233422

Test Description	Value(s)	Reference Range	
Glucose, Fasting (FBS)			
Glucose fasting Method : Fluoride Plasma-F, Hexokinase	75	Normal: 70 - 99 Impaired Tolerance: 100-125 Diabetes mellitus: >= 126 (on more than one occassion) (American diabetes association guidelines 2018)	mg/dL
Urine Fasting	Absent		
Urine Ketones	Absent		

END OF REPORT

Dr. Mohole Bhupendra D.
MBBS, DCP
Reg No. 87339

MADYOASIS DIAGNOSTICS

Patient Name : **MRS. POONAM TEKWANI**
Age/Gender : 34 years (Female)
Mobile No. : -

Referral : SELF
Source : **MEDIHOME**
Sample Collected : Nov 30, 2022, 01:02 p.m.
Sample Received : Nov 30, 2022, 01:02 p.m.
Approved Date : Nov 30, 2022, 04:54 p.m.
Sample ID : 002233422

Test Description	Value(s)	Reference Range	
Hba1C, Glycosylated Hemoglobin			
HbA1c (GLYCOSYLATED HEMOGLOBIN), BLOOD Method : (HPLC, NGSP certified)	5.23	Normal :-4.2 to 6.2 Good control :-5.5 to 6.8 Fair control :- 6.8 to 7.6 Poor control :- >7.6	%
Estimated Average Glucose :	103.40	-	mg/dL

Interpretation

As per American Diabetes Association (ADA)	
Reference Group	HbA1c in %
Non diabetic adults >=18 years	<5.7
At risk (Prediabetes)	5.7 - 6.4
Diagnosing Diabetes	>= 6.5
Therapeutic goals for glycemic control	Age > 19 years Goal of therapy: < 7.0 Action suggested: > 8.0 Age < 19 years Goal of therapy: <7.5

Note:

1. Since HbA1c reflects long term fluctuations in the blood glucose concentration, a diabetic patient who is recently under good control may still have a high concentration of HbA1c. Converse is true for a diabetic previously under good control but now poorly controlled .
2. Target goals of < 7.0 % may be beneficial in patients with short duration of diabetes, long life expectancy and no significant cardiovascular disease. In patients with significant complications of diabetes, limited life expectancy or extensive co-morbid conditions, targeting a goal of < 7.0 % may not be appropriate.

Comments

HbA1c provides an index of average blood glucose levels over the past 8 - 12 weeks and is a much better indicator of long term glycemic control as compared to blood and urinary glucose determinations.

ADA criteria for correlation between HbA1c & Mean plasma glucose levels.

Dr. Mohole Bhupendra D.
MBBS, DCP
Reg. No. 87139

MADYOASIS DIAGNOSTICS

Patient Name : **MRS. POONAM TEKWANI**
Age/Gender : 34 years (Female)
Mobile No. : -

Referral : SELF
Source : **MEDIHOME**
Sample Collected : Nov 30, 2022, 01:02 p.m.
Sample Received : Nov 30, 2022, 01:02 p.m.
Approved Date : Nov 30, 2022, 04:54 p.m.
Sample ID : 002233422

Test Description	Value(s)	Reference Range

HbA1c(%)	Mean Plasma Glucose (mg/dL)
6	126
7	154
8	183
9	212
10	240
11	269
12	298

END OF REPORT

Dr. Mohole Bhupendra D.
MBBS, DCP
Reg. No. 87139

MADYOASIS DIAGNOSTICS

Patient Name : **MRS. POONAM TEKWANI**
Age/Gender : 34 years (Female)
Mobile No. : -

Referral : SELF
Source : **MEDIHOME**
Sample Collected : Nov 30, 2022, 01:02 p.m.
Sample Received : Nov 30, 2022, 01:02 p.m.
Approved Date : Nov 30, 2022, 04:54 p.m.
Sample ID : 002233422

Test Description	Value(s)	Reference Range	
Lipid Profile			
Cholesterol-Total Method : Spectrophotometry	165	Desirable level | < 200 Borderline High | 200-239 High | >or = 240	mg/dL
Triglycerides Method : Serum, Enzymatic, endpoint	95	Normal: < 150 Borderline High: 150-199 High: 200-499 Very High: >= 500	mg/dL
HDL Cholesterol Method : Serum, Direct measure-PEG	**32**	Normal: > 40 Major Risk for Heart: < 40	mg/dL
LDL Cholesterol Method : Enzymatic selective protection	114	Optimal < 100 Near / Above Optimal 100-129 Borderline High 130-159 High 160-189 Very High >or = 190	mg/dL
VLDL Cholesterol Method : Serum, Enzymatic	19	6 - 38	mg/dL
CHOL/HDL Ratio Method : Serum, Enzymatic	**5.16**	3.5 - 5.0	
LDL/HDL Ratio Method : Serum, Enzymatic	**3.56**	2.5 - 3.5	

Note:
8-10 hours fasting sample is required.

END OF REPORT

Dr. Mohole Bhupendra D.
MBBS, DCP
Reg. No. 87339

MADYOASIS DIAGNOSTICS

Patient Name : **MRS. POONAM TEKWANI**
Age/Gender : 34 years (Female)
Mobile No. : -

Referral : SELF
Source : **MEDIHOME**
Sample Collected : Nov 30, 2022, 01:02 p.m.
Sample Received : Nov 30, 2022, 01:02 p.m.
Approved Date : Nov 30, 2022, 04:54 p.m.
Sample ID : 002233422

Test Description	Value(s)	Reference Range	
Kidney Function Panel			
Urea Method : Uricase	28	17 - 43	mg/dL
Blood Urea Nitrogen-BUN Method : Serum, Urease	**59.92**	7 - 18	mg/dL
Creatinine Method : Serum, Jaffe	0.69	0.57 - 1.11	mg/dL
Uric Acid Method : Serum, Uricase	3.2	2.6 - 6.0	mg/dL
Potassium	4.6	3.8 - 5.0 ?Premature cord: 5-10.2 Premature , 48 hrs: 3-6 Newborn cord: 5.6-12 Newborn: 3.7-5.9	mmol/L
Sodium	140	136 - 149 Premature, cord: 116-140 Premature 48 hrs: 128-148 Newborn cord: 126-166 Newborn: 133-146	mmol/L
Chlorides	106	101.00 - 109.00	mmol/L

Remark:

In blood, Urea is usually reported as BUN and expressed in mg/dl. BUN mass units can be converted to urea mass units by multiplying by 2.14.

END OF REPORT

Dr. Mohole Bhupendra D.
MBBS, DCP
Reg. No. 87139

MADYOASIS DIAGNOSTICS

Patient Name : **MRS. POONAM TEKWANI**
Age/Gender : 34 years (Female)
Mobile No. : -

Referral : SELF
Source : **MEDIHOME**
Sample Collected : Nov 30, 2022, 01:02 p.m.
Sample Received : Nov 30, 2022, 01:02 p.m.
Approved Date : Nov 30, 2022, 04:54 p.m.
Sample ID : 002233422

Test Description	Value(s)	Reference Range	
Lft, Liver Function Test			
Total Protein Method : Serum, Biuret, reagent blank end point	6.8	6.6 - 8.3	g/dL
Albumin Method : Serum, Bromocresol green	3.8	3.2 - 4.6	g/dL
Globulin Method : Serum, EIA	3	1.8 - 3.6	g/dL
A/G Ratio Method : Serum, EIA	1.27	1.2 - 2.2	
Bilirubin - Total Method : Serum, Jendrassik Grof	0.8	0.3 - 1.2	mg/dL
Bilirubin - Direct Method : Serum, Diazotization	0.2	< 0.2	mg/dL
Bilirubin - Indirect Method : Serum, Calculated	0.60	0.1 - 1.0	mg/dL
SGOT Method : Serum, UV with P5P, IFCC 37 degree	20	< 35	U/L
SGPT Method : Serum, UV with P5P, IFCC 37 degree	18	< 35	U/L
Alkaline Phosphatase Method : PNPP-AMP Buffer/Kinetic	98	30 - 120	U/L
GGT-Gamma Glutamyl Transpeptidae Method : Serum, G-glutamyl-carboxy-nitoanilide	25	< 38	U/L

END OF REPORT

Dr. Mohole Bhupendra D.
MBBS, DCP
Reg. No. 87139

MADYOASIS DIAGNOSTICS

Patient Name : **MRS. POONAM TEKWANI**
Age/Gender : 34 years (Female)
Mobile No. : -

Referral : SELF
Source : **MEDIHOME**
Sample Collected : Nov 30, 2022, 01:02 p.m.
Sample Received : Nov 30, 2022, 01:02 p.m.
Approved Date : Nov 30, 2022, 04:54 p.m.
Sample ID : 002233422

Test Description	Value(s)	Reference Range	
Thyroid Profile (T3, T4, Tsh)			
T3-Total	98	82 - 213	ng/dL
T4-Total	10.6	6.09 - 12.23	ug/dL
TSH-Ultrasensitive	2.52	0.45 - 4.5	uIU/mL
Method : CLIA		First Trimester : 0.1-2.5	
		Second Trimester : 0.2-3.0	
		Third trimester : 0.3-3.0	

Interpretation

TSH	T3	T4	Suggested Interpretation for the Thyroid Function Tests Pattern
Raised	Within range	Within range	Raised Within Range Within Range .Isolated High TSHespecially in the range of 4.7 to 15 m1U/m1 is commonly associated with Physiological & Biological TSH Variability. Subclinical Autoimmune Hypothyroidism,Intermittent 14 therapy for hypothyroidism .Recovery phase after Non-Thyroidal illness*
Raised	Decreased	Decreased	Chronic Autoimmune Thyroiditis Post thyroidectomy,Post radioiodine Hypothyroid phase of transient thyroiditis*
Raised or within range	Raised	Raised or within range	Interfering antibodies to thyroid hormones (anti-TPO antibodies)Intermittent 14 therapy or T4 overdose •Drug interference-Amiodarone, Heparin,Beta blockers,steroids, anti-epileptics.
Decreased	Raised or within range	Raised or within range	Isolated Low TSH -especially in the range of 0.1 to 0.4 often seen in elderly & Range Range associated with Non-Thyroidal illness .Subclinical Hyperthyroidism .Thyroxine ingestion'
Decreased	Decreased	Decreased	Central Hypothyroidism .Non-Thyroidal illness .Recent treatment for Hyperthyroidism (TSH remains suppressed)*
Decreased	Raised	Raised	Primary Hyperthyroidism (Graves' disease),Multinodular goitre, Toxic nodule •Transient thyroiditis:Postpartum, Silent (lymphocytic), Postviral (granulomatous,subacute. DeQuervain's),Gestational thyrotoxicosis with hyperemesis gravidarum*
Decreased Within Rang	Raised	Within range	T3 toxicosis •Non-Thyroidal illness
Within range	Decreased	Within range	Isolated Low T3-often seen in elderly & associated Non-Thyroidal illness In elderly the drop in 13 level can be upto 25%.

END OF REPORT

Dr. Mohole Bhupendra D.
MBBS, DCP
Reg. No. 87130

MADYOASIS DIAGNOSTICS

Patient Name : **MRS. POONAM TEKWANI**
Age/Gender : 34 years (Female)
Mobile No. : -

Referral : SELF
Source : **MEDIHOME**
Sample Collected : Nov 30, 2022, 01:02 p.m.
Sample Received : Nov 30, 2022, 01:02 p.m.
Approved Date : Nov 30, 2022, 04:54 p.m.
Sample ID : 002233422

Test Description	Value(s)	Reference Range
Hiv 1 & 2 Rapid Test		
HIV 1	Negative	
Method : Immunochromatography		
HIV 2	Negative	

Note

- All reactive samples are tested by 3 different methods as per NACO guidelines, 2010.
- The test results obtained relate only to the sample given or recieved.

END OF REPORT

Dr. Mohole Bhupendra D.
MBBS, DCP
Reg. No. 87330

MADYOASIS DIAGNOSTICS

Patient Name : **MRS. POONAM TEKWANI**
Age/Gender : 34 years (Female)
Mobile No. : -

Referral : SELF
Source : **MEDIHOME**
Sample Collected : Nov 30, 2022, 01:02 p.m.
Sample Received : Nov 30, 2022, 01:02 p.m.
Approved Date : Nov 30, 2022, 04:54 p.m.
Sample ID : 002233422

Test Description	Value(s)	Reference Range
Hepatitis B Surface Antigen (Hbsag) Australia Antigen, Rapid Card		
Hepatitis B Surface Antigen (HBSAg)-Rapid Screening	Non Reactive	Non Reactive

Method : Serum, Immunochromatography

Remark:

All Reactive results must be confirmed by Neutralizing confirmatory test or by HBV DNA detection assay.

END OF REPORT

Dr. Mohole Bhupendra D.
MBBS, DCP
Reg. No. 87339

MADYOASIS DIAGNOSTICS

Patient Name : **MRS. POONAM TEKWANI**
Age/Gender : 34 years (Female)
Mobile No. : -

Referral : SELF
Source : **MEDIHOME**
Sample Collected : Nov 30, 2022, 01:02 p.m.
Sample Received : Nov 30, 2022, 01:02 p.m.
Approved Date : Nov 30, 2022, 04:54 p.m.
Sample ID : 002233422

Test Description	Value(s)	Reference Range
Vdrl (Rpr), Serum		
VDRL Test for Syphilis	NON REACTIVE	

COMMENTS

- False positive results may be seen during a variety of acute and chronic conditions
- Reactive results must be correlated with supportive clinical, historical and epidemiological evidence to arrive at a final diagnosis
- TPHA/FTA-Abs is a confirmatory test for Treponema Pallidum with very high specificity and sensitivity

END OF REPORT

Dr. Mahesh Bhagwatkar D.
MBBS, DCP
Reg. No. 87138

MADYOASIS DIAGNOSTICS

Patient Name : **MRS. POONAM TEKWANI**
Age/Gender : 34 years (Female)
Mobile No. : -

Referral : SELF
Source : **MEDIHOME**
Sample Collected : Nov 30, 2022, 01:02 p.m.
Sample Received : Nov 30, 2022, 01:02 p.m.
Approved Date : Nov 30, 2022, 04:54 p.m.
Sample ID : 002233422

Test Description	Value(s)	Reference Range	
Routine Examination Of Urine			
General Examination			
Colour	PALE YELLOW	Pale Yellow	
Transparency (Appearance)	CLEAR	Clear	
Deposit	Absent	Absent	
Reaction (pH)	Acidic 6.5	4.5 - 7.0	
Specific gravity	1.020	1.005 - 1.030	
Chemical Examination			
Urine Protein (Albumin)	Absent	Absent	
Urine Ketones (Acetone)	Absent	Absent	
Urine Glucose (Sugar)	Absent	Absent	
Bile salts	Absent	Absent	
Urobilinogen	Normal	Normal	
Nitrite	Negative	Negative	
Microscopic Examination			
Red blood cells	Absent	0-4	/hpf
Pus cells (WBCs)	3 - 4 /HPF	0-9	/hpf
Epithelial cells	1 - 2 /HPF	0-4	/hpf
Crystals	Absent	Absent	
Cast	Absent	Absent	
Amorphous deposits	Absent	Absent	
Bacteria	Absent	Absent	
Trichomonas Vaginalis	Absent	Absent	
Yeast cells	Absent	Absent	

END OF REPORT

Dr. Mohole Bhupendra D.
MBBS, DCP
Reg. No. 87139